DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Prohance (Gadoteridol) - Summary


Manufactured for
Bracco Diagnostics Inc.
Princeton, NJ 08543
by Nycomed GmbH
78224 Singen (Germany)

Revised September 2007


Gadolinium-based contrast agents increase the risk for nephrogenic systemic fibrosis (NSF) in patients with:

  • acute or chronic severe renal insufficiency (glomerular filtration rate < 30 mL/min/1.73m2), or
  • acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.

In these patients, avoid use of gadolinium-based contrast agents unless the diagnostic information is essential and not available with non-contrast enhanced magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs. Screen all patients for renal dysfunction by obtaining a history and/or laboratory tests. When administering a gadolinium-based contrast agent, do not exceed the recommended dose and allow a sufficient period of time for elimination of the agent from the body prior to any readministration (See WARNINGS).



(Gadoteridol Injection)

ProHance (Gadoteridol Injection) is a nonionic contrast medium for magnetic resonance imaging (MRI), available as a 0.5M sterile clear colorless to slightly yellow aqueous solution in vials and syringes for intravenous injection.

Central Nervous System

ProHance (Gadoteridol Injection) is indicated for use in MRI in adults and children over 2 years of age to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues.

Extracranial/Extraspinal Tissues

ProHance is indicated for use in MRI in adults to visualize lesions in the head and neck.

See all Prohance indications & dosage >>


Media Articles Related to Prohance (Gadoteridol)

The Biology of Borderline (and a Diagnostic Tip)
Source: Medscape NeurologyHeadlines [2015.03.23]
Dr Derick Vergne on the challenges of diagnosing borderline personality disorder and some of the unique factors that contribute to its pathophysiology.
Medscape Psychiatry

Study examines diagnostic accuracy of pathologists interpreting breast biopsies
Source: Breast Cancer News From Medical News Today [2015.03.20]
In a study in which pathologists provided diagnostic interpretation of breast biopsy slides, overall agreement between the individual pathologists' interpretations and that of an expert consensus...

Comparing the diagnostic criteria for the DSM-5 and ICD-10
Source: Alcohol / Addiction / Illegal Drugs News From Medical News Today [2015.03.19]
Both the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5), and the International Statistical Classification of Diseases and Related Health Problems, 10th Edition (ICD-10)...

ACC: CT No Better Than Stress Test as Chest Pain Diagnostic (CME/CE)
Source: MedPage Today Radiology [2015.03.14]
(MedPage Today) -- No difference in outcomes but more radiation with CT angiography.

Cochrane Review of effectiveness of point of care diagnostics for schistosomiasis
Source: Tropical Diseases News From Medical News Today [2015.03.13]
Researchers from the Cochrane Infectious Disease Group, hosted at LSTM, have conducted an independent review to assess how well point of care tests detect Schistosoma infections in people living in...

more news >>

Published Studies Related to Prohance (Gadoteridol)

Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases. [2011.07]
OBJECTIVES: To determine the efficacy and safety of 2 doses of gadobutrol 1.0 M (0.1 and 0.2 mmol/kg body weight [BW]), compared with gadoteridol 0.5 M (0.2 mmol/kg BW), in contrast-enhanced magnetic resonance imaging (CE-MRI) of brain metastases in patients with known or suspected brain metastases from systemic malignancies. The study also compared the usefulness of gadobutrol in treatment planning for stereotactic radiosurgery (SRS)... CONCLUSION: In this study, a single dose of gadobutrol was shown to be noninferior to a double dose of gadoteridol at detecting brain metastases, and could be effectively used for treatment planning in patients eligible for SRS. A dose of gadobutrol 0.1 mmol/kg BW is recommended as the clinical dose for the detection of brain metastases.

Magnetic resonance evaluation of brain metastases from systemic malignances with two doses of gadobutrol 1.0 m compared with gadoteridol: a multicenter, phase ii/iii study in patients with known or suspected brain metastases. [2011]
planning for stereotactic radiosurgery (SRS)... CONCLUSION: In this study, a single dose of gadobutrol was shown to be

Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. [2008.05]
BACKGROUND AND OBJECTIVES: Recent studies strongly link nephrogenic systemic fibrosis to gadolinium administration for magnetic resonance imaging. In a recent advisory, the Food and Drug Administration stated that all gadolinium-containing chelates are potentially associated with nephrogenic systemic fibrosis; however, most reported cases are linked to gadodiamide (Omniscan) and gadopentetate dimeglumine (Magnevist). Given the severe consequences of nephrogenic systemic fibrosis, it is critical to define the risks associated with each gadolinium-containing chelate. The purpose of this study was to examine nephrogenic systemic fibrosis risk in a hemodialysis population exposed to gadoteridol (ProHance)... CONCLUSIONS: It is concluded that the risk for nephrogenic systemic fibrosis with gadoteridol in patients who are on long-term hemodialysis may be lower than with gadodiamide and gadopentetate dimeglumine.

more studies >>

Clinical Trials Related to Prohance (Gadoteridol)

SH L 562BB Phase II/III Dose Justification and Gadoteridol-Controlled Comparative Study [Recruiting]
This study is conducted to compare the contrast effect and safety of SH L562BB with ProHance, which has already been approved as a pharmaceutical product of similar indication.

Safety and Efficacy of Gadobutrol 1.0 Molar (Gadovist®) in Patients for Central Nervous System (CNS) Imaging [Recruiting]
This study involves the use of Magnetic Resonance Imaging (MRI) contrast agents called gadobutrol (Gadovist) Injection and ProHance Injection. The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of gadobutrol when used for taking MR images of the brain and spine. The results of the MRI with gadobutrol Injection will be compared to the results of MR images taken without contrast and with the results of the MR images taken with ProHance.

Evaluation of the Risk of NSF Following ProHance Injection in Patients With Chronic Kidney Disease [Recruiting]
The objective of this long term study is to prospectively compare the incidence of NSF in two cohorts (Cohort 1- patients with moderate chronic kidney disease eGFR 30-59 and Cohort 2- patients with severe chronic kidney disease or kidney failure eGFR <30).

Regadenoson Blood Flow in Type 1 Diabetes (RABITĀ¹D) [Not yet recruiting]
Cardiovascular disease (CVD) remains the major cause of mortality and morbidity in both type 1 (T1D) and type 2 (T2D) diabetes patients; modifications of traditional CVD risk factors have had a limited impact. This project called Regadenoson Blood flow in Type 1 Diabetes (RABITD) and is proposed as a sub-study of the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study, which has established a unique cohort of 656 T1D patients (age 20-55, minimal diabetes duration of 10 yrs) and 764 non-diabetic controls. This cohort is being followed for progression of coronary artery calcification (CAC) measured using the electron beam tomography (EBT) for development of clinical CVD. Participants have been well characterized during the baseline examination (4/00-3/02) and two follow-up re-examinations 3 and 6 years later. The study has provided important insights into the risk factors and possible prevention of premature CVD in T1D. We are proposing assess a subset of this population to determine vasodilatory reserve as it relates to early coronary atherosclerosis in T1D.

Hypothesis: that myocardial blood imaging (MBF) reserve can be measured in Type 1 DM using regadenoson stress cardiac magnetic resonance and that significantly reduced MBF is a marker of extensive artherosclerotic disease correlated to coronary arterial calcification, plaque formation and impaired vasodilatory reserve.

Specific Aims:

1. Determine the relationship between myocardial perfusion index (previously determined), regional CBF and invasively measured coronary flow reserve

2. Measure coronary blood flow using regadenoson stress CMR and determine the myocardial blood flow reserve in type 1 DM subjects compared to non-diabetic controls.

3. Determine the relationship between CBF reserve in vascular distributions to the degree of coronary arterial calcification.

4. Determine the severity of CBF blood flow reduction and the relationship to perfusion reserve measured by invasive coronary Doppler flow-wire under regadenoson between in type 1 DM subjects compared to non-diabetic controls.

more trials >>

Reports of Suspected Prohance (Gadoteridol) Side Effects

Nephrogenic Systemic Fibrosis (114)Pain (90)Skin Induration (65)Mobility Decreased (63)Anxiety (59)Skin Tightness (56)Joint Range of Motion Decreased (53)Oedema Peripheral (51)Emotional Distress (51)Skin Hypertrophy (46)more >>

Page last updated: 2015-03-23

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015